Cortisol

Other Names

(11β)-11,17,21-Trihydroxypregn-4-ene-3,20-dione(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3(5H)-one11beta,17alpha,21-Trihydroxypregn-4-ene-3,20-dione11β,17α,21-Trihydroxypregn-4-ene-3,20-dione17-Hydroxycorticosterone4-Pregnene-11β,17α,21-triol-3,20-dioneCortisol alcoholDihydrocortisoneHydrocorticosteroneHydrocortisoneHydroxycortisoneKendall's compound FReichstein's substance M

Synopsis

Cortisol (Hydrocortisone): A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Classification

Cortisol — also known clinically and pharmacologically as hydrocortisone — is the primary endogenous glucocorticoid hormone in humans. Glucocorticoids are 21-carbon corticosteroid hormones derived from cholesterol in the adrenal gland, under control of the hypothalamic-pituitary-adrenal (HPA) axis. Its systematic IUPAC name is 11β,17,21-trihydroxypregn-4-ene-3,20-dione, and it was historically designated Kendall's compound F and Reichstein's substance Fa during the early research period that led to its isolation. Kendall's compound F was later identified as 17-hydroxycorticosterone (cortisol or hydrocortisone).

Cortisol is a glucocorticoid steroid hormone, released by the adrenal glands in response to biochemical stress. In humans, cortisol is the main physiological glucocorticoid, and it acts via binding to the glucocorticoid receptor (GR), a member of the highly conserved nuclear receptor subfamily 3 group of intracellular hormone receptors.

Molecular Structure and Stereochemistry

Cortisol is a C-21 steroid built on the cholesterol-derived pregnane backbone. Cortisol possesses eight chiral centers, located at C8, C9, C10, C13, C14, C17, C11, and C20 in its structure, with the natural enantiomer featuring a 5α (A/B trans) junction critical for receptor binding affinity. This stereochemistry arises during enzymatic reductions in biosynthesis, ensuring the active 11β-hydroxy configuration. The presence of multiple chiral centers contributes to cortisol's specificity, as diastereomers like 11-deoxycortisol lack full activity.

Natural Source and Endogenous Production

Cortisol is synthesized from cholesterol and secreted from the zona fasciculata of the adrenal cortex. In the bloodstream, cortisol is mostly bound up by Cortisol Binding Globulin (CBG) and albumin, leaving only about 1–3% bioavailable to enter tissues and invoke a biological response. The raw material for cortisol production is mainly cholesterol, accounting for 80% of the total cortisol production, the remaining 20% being synthesized by the adrenal cortex.

Common Forms and Preparations

Cortisol itself is not found as a dietary supplement ingredient in concentrated botanical extracts, but its synthetic identical, hydrocortisone, is available in pharmaceutical form. The majority of existing marketed oral formulations of hydrocortisone are provided at doses of 5 mg, 10 mg, and 20 mg and are designed to deliver "immediate-release" of the active ingredient. It is also available as topical creams, injectable solutions, intravenous preparations, and novel modified-release oral tablets (such as Plenadren®). The term "cortisol supplement" in the commercial marketplace most commonly refers to multi-ingredient products containing botanical adaptogens and nutrients intended to modulate cortisol levels — not products containing cortisol itself as an ingredient.

2. Historical Background and Discovery

Early Understanding of the Adrenal Cortex

Cortisol's story begins in the mid-19th century, when British physician Thomas Addison established the role of the adrenal cortex and first described symptoms of adrenal deficiency, now known as Addison's disease. When Thomas Addison first described this disorder in the 19th century, the most common cause was destruction of the adrenal cortex due to tuberculosis. Addison's 1855 monograph drew attention to the essential and hitherto unknown functions of these glands atop the kidneys.

Isolation and Chemical Characterization (1930s)

In the mid-1930s, Edward Kendall and Tadeus Reichstein succeeded in isolating and analyzing the composition of a number of similar hormones derived from the adrenal cortex. In the 1930s, Edward Kendall, working at the Mayo Clinic in Rochester, Minnesota, isolated six hormones from adrenal glands, naming them for the order in which they were isolated: compounds A through F. In 1936, Reichstein isolated seven compounds, also including cortisol and cortisone (it would later be discovered that cortisone was actually a metabolite of cortisol).

Reichstein and his colleagues isolated about 29 hormones and determined their structure and chemical composition. The isolation of pure cortisol in meaningful quantities was extraordinarily difficult: Kendall, using 3,000 pounds of animal adrenal glands, was only able to produce 1 g of compound A.

Clinical Translation and the Nobel Prize

A decade later, rheumatologist Philip Hench showed that cortisol, and specifically its derivative cortisone, could be used to treat rheumatoid arthritis and other inflammatory conditions. In the mid-1930s, Kendall and Reichstein succeeded in isolating and analyzing the composition of a number of similar hormones derived from the adrenal cortex, which became the basis for cortisone preparations that, with input from Kendall and Philip Hench, were used at the end of the 1940s to treat rheumatoid arthritis and other inflammations.

The Nobel Prize in Physiology or Medicine 1950 was awarded jointly to Edward Calvin Kendall, Tadeus Reichstein, and Philip Showalter Hench "for their discoveries relating to the hormones of the adrenal cortex, their structure and biological effects." A year after Hench presented his findings at the Mayo Clinic in 1949, Hench, Kendall, and Reichstein were awarded the Nobel Prize for their work on the hormones of the adrenal cortex.

Traditional and Pre-Scientific Use

Cortisol is an endogenous hormone rather than a plant-derived or exogenously consumed substance in the traditional sense; as such, it does not have a history of isolated use in traditional medicine systems. The adrenal gland extracts prepared in the early 20th century from animal sources (bovine and porcine adrenal glands) were among the earliest attempts at what could loosely be termed "glandular supplementation," though these were crude preparations later superseded by pure pharmaceutical-grade hydrocortisone. The clinical and experimental investigations of the 1930s–1940s represent the foundational period of applied cortisol science rather than a traditional ethnobotanical history.

3. Biosynthesis: Key Constituents and Active Compounds

The Steroidogenic Pathway

Cortisol is synthesized from pregnenolone derived from cholesterol by removal of the side chain at C20, catalyzed by cytochrome P450scc (CYP11A1) at the mitochondria. Newly synthesized pregnenolone moves into the endoplasmic reticulum, where it is converted to 17-hydroxypregnenolone by CYP17 or to progesterone by 3β-hydroxysteroid dehydrogenase (3β-HSD). 17-hydroxyprogesterone is converted to 11-deoxycortisol by the 21α-hydroxylase activity of CYP21, and then 11-deoxycortisol moves to the mitochondria from the endoplasmic reticulum. For the final step of cortisol biosynthesis, 11-deoxycortisol receives 11β-hydroxylation, catalyzed by CYP11B1 or CYP11B2.

The enzyme 11β-hydroxylase, encoded by CYP11B1, catalyzes the stereospecific addition of a hydroxyl group at C11 of 11-deoxycortisol, transforming it into active cortisol and completing glucocorticoid biosynthesis. Located in the mitochondria of zona fasciculata cells, it requires molecular oxygen and NADPH for function.

HPA Axis Regulation

The hypothalamic-pituitary-adrenal (HPA) axis is the central neuroendocrine system orchestrating cortisol release, involving CRH from the hypothalamus, ACTH from the pituitary, and cortisol feedback from the adrenals. The hypothalamus secretes corticotropin-releasing hormone (CRH), which causes cells in the anterior pituitary to release adrenocorticotropin hormone (ACTH) into the vascular system. ACTH is transported to the adrenal cortex via the blood, where it increases low density lipoprotein receptors and cholesterol desmolase. Increased cortisol levels suppress the release of CRH and ACTH in a negative feedback loop that keeps all three in check.

The HPA axis follows a circadian rhythm, giving cortisol a diurnal cycle with higher levels in the morning and lower levels in the evening. CRH can be released in response to stress, intensive exercise, low blood glucose levels, and viral infections.

Cortisol Metabolism

The main downstream product of reversible cortisol metabolism is cortisone, occurring via the 11-beta hydroxysteroid dehydrogenase system (11-beta HSD1 and 11-beta HSD2). Any cortisol and cortisone products that are not needed are broken down into tetrahydrometabolites in the liver, before being flushed out in urine.

11β-hydroxysteroid (type II) dehydrogenase, by converting cortisol to its inert form cortisone, prevents cortisol activation of mineralocorticoid receptors. However, when cortisol levels are high and 11β-HSD is saturated, cortisol can activate mineralocorticoid receptors — usually a result of treatment with exogenous glucocorticoids at supra-physiologic doses.

Of note, cortisol, and many synthetic glucocorticoids, are natural agonists of the mineralocorticoid receptor (MR), binding with up to 100-fold the affinity of the hormone for GR; however, transcriptional regulation by cortisol via GR is much more pronounced than via MR.

4. Mechanisms of Action

Glucocorticoid Receptor Signaling

The physiological and pharmacological actions of glucocorticoids are mediated by the glucocorticoid receptor (GR), a member of the nuclear receptor superfamily of ligand-dependent transcription factors. In the absence of hormone, GR resides predominantly in the cytoplasm of cells as part of a large multi-protein complex that includes chaperone proteins (hsp90, hsp70, and p23) and immunophilins of the FK506 family (FKBP51 and FKBP52). These proteins maintain the receptor in a conformation that is transcriptionally inactive but favors high-affinity ligand binding.

Upon binding to an intracellular cytoplasmic glucocorticoid receptor (GR), the cortisol-GR complex is translocated inside the nucleus. Ligand binding to GR results predominantly in transcriptional regulation, and in some conditions and tissues, glucocorticoids may regulate up to 20% of the genome.

Ligand-occupied GR induces or represses the transcription of thousands of genes by direct binding to DNA response elements and/or by physically associating with other transcription factors. The traditional view that glucocorticoids act through a single GR protein has changed dramatically with the discovery of a large cohort of receptor isoforms with unique expression, gene-regulatory, and functional profiles.

Transactivation and Transrepression

The activated GCR complex upregulates the expression of anti-inflammatory proteins in the nucleus (a process known as transactivation) and represses the expression of pro-inflammatory proteins in the cytosol by preventing the translocation of other transcription factors from the cytosol into the nucleus (transrepression). This dual-mode of gene regulation is fundamental to cortisol's ability to both stimulate and suppress different physiological processes simultaneously.

Genomic vs. Non-Genomic Actions

Once synthesized and released into the bloodstream, cortisol exerts its physiological effects. The molecular structure of cortisol can pass through cell membranes and bind directly to nuclear receptors, altering gene expression with remarkable precision. In addition to classical genomic (nuclear receptor-mediated) actions that take hours, cortisol also initiates rapid non-genomic effects at the cell membrane, though detailed characterization of these pathways continues to be an active area of research.

Transport in Circulation

Cortisol, the most abundant endogenous glucocorticoid in man, is transported in the blood predominantly bound to corticosteroid-binding globulin (CBG). CBG not only facilitates cortisol distribution but also plays a role in its release to tissues.

5. Physiological Roles and Body Systems

Metabolic Functions

The primary biological function of cortisol is to regulate the production and the provision of carbohydrates for the brain and other metabolically active tissues. Increased cortisol production and secretion is a normal physiological response to stress and leads to the essential mobilization of fats, proteins, and carbohydrates to cover increased physical energy demand.

Glucocorticoids have a pivotal role in the glucose, protein, and fat metabolism of the body. Cortisol affects metabolism by helping regulate how the body uses glucose (sugar) for energy. For example, cortisol triggers the pancreas to decrease insulin and increase glucagon; insulin lowers blood glucose.

It is paradoxical that cortisol promotes not only gluconeogenesis (biosynthesis of glucose molecules) in the liver, but also glycogenesis (polymerization of glucose molecules into glycogen); cortisol is thus better thought of as stimulating glucose/glycogen turnover.

Immune Modulation and Anti-Inflammatory Action

Glucocorticoids exert pleiotropic effects on all tissues to regulate cellular and metabolic homeostasis, including the response to stress, inflammation, metabolism, sodium and water balance, and reproductive function. Their medical significance arises from their anti-inflammatory, anti-allergic, and immune-suppressive role in the body.

Cortisol is a particularly plausible candidate for immune regulation because, first, it displays high-amplitude circadian rhythms in serum abundance, and, second, it has a prominent inhibitory function on proinflammatory cytokine transcription. While short-term cortisol elevation helps resolve inflammation, chronic elevation can suppress immune function, making individuals more susceptible to infections and slowing wound healing.

Circadian Rhythm and Sleep

Most people have lower cortisol levels in the evening when they go to sleep and peak levels in the morning right before they wake up. This suggests that cortisol plays a key role in the circadian rhythm and how the body wakes up. The glucocorticoid hormone cortisol acts throughout the body to support circadian processes and adaptation to stress.

Cardiovascular System

Hypertension is present in about 80% of patients with Cushing's syndrome and can lead to significant morbidity and mortality. Several pathogenic mechanisms have been proposed for glucocorticoid-induced hypertension including a functional mineralocorticoid excess state, up-regulation of the renin-angiotensin system, and deleterious effects of cortisol on the vasculature.

Neurological and Psychiatric Dimensions

The relationship between cortisol dysregulation and major depressive disorder is complex, characterized by HPA axis hyperactivity and chronic inflammation. Elevated or dysregulated cortisol levels are linked to mood disorders, including anxiety and depression, where both high and low cortisol can impair cognitive function and emotional stability.

The relationship between cortisol levels and cognition often follows an "inverted U" pattern, where both low and high cortisol levels can impair cognitive performance, but moderate levels may enhance certain cognitive functions. Persistent hypercortisolemia can lead to hippocampal atrophy and cognitive deficits associated with bipolar disorder.

The prolonged activation of the HPA axis disrupts cortisol regulation, leading to the decline of both physical and mental health. The chronic stress-induced HPA axis dysfunction interacts with inflammatory pathways and generates oxidative stress, contributing to cellular damage and neuroinflammation that further aggravates depressive symptoms.

6. Scientific Evidence by Clinical Area

6.1 Adrenal Insufficiency (Addison's Disease) — Replacement Therapy

This represents the best-established and most rigorously studied application of exogenous cortisol (as hydrocortisone). The Endocrine Society Clinical Practice Guideline recommends once-daily fludrocortisone (median 0.1 mg) and hydrocortisone (15–25 mg/d) or cortisone acetate replacement (20–35 mg/d) applied in two to three daily doses in adults.

In order to achieve efficacious plasma levels of hydrocortisone, multiple daily dosing is required (typically 2 or 3 times daily), which results in high peak-to-trough fluctuations in plasma concentrations. Due to the half-life of hydrocortisone of approximately 90 minutes, three or four doses per day are recommended to mimic physiologic cortisol release.

Despite glucocorticoid-replacement therapy, patients with adrenal insufficiency have a greater cardiovascular risk than the general population, and suffer from impaired health-related quality of life. Although the aim of the replacement GC therapy is to reproduce as much as possible the physiological pattern of cortisol secretion by the normal adrenal gland, the pharmacokinetics of available oral immediate-release hydrocortisone or cortisone make it impossible to fully mimic the cortisol rhythm.

Evidence strength: Strong — Endocrine Society clinical practice guidelines, multiple controlled clinical trials, and long-term real-world cohort studies support hydrocortisone replacement as the standard of care in adrenal insufficiency. The evidence base is robust and the application is a defined medical indication, not a wellness supplement context.

6.2 Cushing's Syndrome (Hypercortisolism)

Cushing's syndrome is generally defined as a state of glucocorticoid excess. It can be caused by endogenous production of cortisol from the adrenal gland (regardless of the reason) or by synthetic glucocorticoids administered therapeutically for any number of diseases. Hypercortisolism is the clinical state resulting from excessive tissue exposure to cortisol or other glucocorticoids, from exogenous or endogenous sources. When sustained over time, hypercortisolism produces the distinctive constellation of clinical signs and symptoms known as Cushing syndrome.

According to the 2008 Endocrine Society guidelines, any of the following tests can be used for the initial diagnosis of Cushing's syndrome: 24-hour urinary free cortisol, late-night salivary cortisol, or a dexamethasone suppression test. Surgical excision of the cause of excess glucocorticoids remains the optimal treatment for Cushing's syndrome. Anti-glucocorticoid and antihypertensive agents and steroidogenesis inhibitors can be used as adjunctive treatment modalities.

Evidence strength: Strong for diagnostic criteria and treatment algorithms. Cushing's syndrome is a well-characterized disorder managed through established endocrine medicine guidelines.

6.3 Cortisol, Mental Health, and Psychiatric Disorders

Chronic stress significantly contributes to the development of depressive disorders, with the HPA axis playing a central role in mediating stress responses. Neurobiological alterations in the hippocampus are linked to HPA axis dysregulation in chronic stress-associated depressive disorders.

In children, chronic stress and high cortisol exposure can lead to long-term behavioral problems, affecting memory, decision-making, and emotional regulation, especially when early-life adversity is present. Similarly, in adults, prolonged cortisol dysregulation often contributes to cognitive decline, mood instability, and an increased vulnerability to psychiatric conditions like major depressive disorder and bipolar disorder.

HPA axis dysfunction manifests as hypocortisolism, abnormal stress responsiveness, or disrupted cortisol rhythms. Chronic stress often initially causes persistently elevated cortisol levels, leading to desensitization and worsening dysfunction, increasing risks for cardiovascular, metabolic, immune, and mental health disorders, and cognitive impairment, including possible links to neurodegenerative diseases.

Evidence strength: Moderate to strong for cortisol dysregulation as a biomarker and pathophysiological contributor to depression, anxiety, and cognitive impairment. However, the causal direction and therapeutic implications are still being refined; most evidence is observational, mechanistic, or from animal models, with fewer interventional human trials specifically targeting cortisol normalization as the primary endpoint.

6.4 Cortisol and Metabolic Syndrome / Cardiovascular Risk

Chronically elevated cortisol can lead to insulin resistance, elevated blood glucose, and increased abdominal fat storage — key components of metabolic syndrome. Chronic stress often initially causes persistently elevated cortisol levels, leading to desensitization and worsening dysfunction, increasing risks for cardiovascular and metabolic disorders.

Evidence strength: Moderate. Associations between chronic hypercortisolism and metabolic syndrome components are well documented in Cushing's syndrome patients. The degree to which subclinical elevations in "normal-range" cortisol independently predict metabolic outcomes in the general population is still an active area of investigation.

6.5 Cortisol and Neurodegenerative Disease

Examination of the multifaceted interplay between cortisol and various diseases reveals implications of cortisol and HPA axis dysregulation for the onset, progression, and potential prevention pathways of conditions such as depression, Alzheimer's disease, and Parkinson's disease. However, the published literature as of 2025 identifies these relationships primarily through observational, epidemiological, and mechanistic studies. Prospective interventional trials targeting cortisol to prevent neurodegeneration in humans remain limited.

Evidence strength: Preliminary. Current evidence is largely mechanistic and observational; the field awaits larger-scale interventional clinical trials.

7. Clinical Measurement and Diagnostic Testing

Several methods have been described for the quantitative measurement of cortisol in both serum and urine. The most widely used methods in routine clinical laboratories are immunoassays (IA) and enzyme immunoassays (EIA), luminescence and fluorescence assays, which are available in numerous commercial kits and on automated platforms.

More specific chromatographic methods have been introduced, such as high-pressure liquid chromatographic (HPLC) or liquid chromatography tandem mass spectrometric assays (LC-MS/MS). The high specificity especially of LC-MS/MS facilitates reliable measurement of cortisol in plasma, urine, and saliva samples.

Salivary cortisol reflects changes in unbound serum cortisol and offers a reliable alternative to measuring free cortisol in serum. Saliva collection at four time points throughout the day (morning, noon, evening, and night) provides a simple and convenient means for assessing not only the bioavailability of cortisol but also its circadian pattern of synthesis — the diurnal cortisol curve.

The gold standard test of HPA axis function is the insulin tolerance test (ITT), in which insulin-induced hypoglycaemia stimulates the hypothalamus, resulting in CRH release and an increase in serum cortisol. Cortisol exists in the urine in free (unconjugated) and conjugated (e.g., glucuronide-conjugated and sulfate-conjugated) forms.

The particular characteristics of cortisol metabolism and the lack of specificity of immunoassays cause marked differences between both methods, highly dependent on the biological matrix in which cortisol is measured. Understanding the origin of these differences is essential for the interpretation of results. Although cross-reactivity with endogenous steroids leads to grossly inaccurate results of immunoassay measurements of cortisol in saliva and urine, preliminary evidence suggests that the clinical sensitivity of Cushing's syndrome screening using immunoassays may be similar to that using mass spectrometry.

8. Dosage Forms and Reported Dosages

Replacement Therapy in Adrenal Insufficiency

Hydrocortisone 15–25 mg/day or cortisone acetate 20–35 mg/day, applied in two to three daily doses in adults, as recommended by the Endocrine Society Clinical Practice Guideline.
Oral immediate-release tablets are most commonly provided at doses of 5 mg, 10 mg, and 20 mg.
In at least one documented case of rapid hydrocortisone metabolism with Addison's disease, an individualized dose split of 25 mg in the morning and 5 mg in the late afternoon yielded clinical improvement.

Acute Adrenal Crisis (Intravenous)

An alternative method of hydrocortisone administration in acute crisis is 100 mg as an IV bolus every 6–8 hours.
After 2–3 days, the stress hydrocortisone dose should be reduced to 100–150 mg, infused over a 24-hour period, irrespective of the patient's clinical status.

Sick-Day Rules in Adrenal Insufficiency

The Addison patient must, in situations of intercurrent illness, increase replacement doses 2 to 3-fold. It is controversial as to whether there is a need to increase the dose by less stressful events and tasks, such as average to vigorous physical activity and mental stress.

Pharmaceutical Formulations

Although the aim of replacement glucocorticoid therapy is to reproduce as much as possible the physiological pattern of cortisol secretion by the normal adrenal gland, the pharmacokinetics of available oral immediate-release hydrocortisone or cortisone make it impossible to fully mimic the cortisol rhythm. Therefore, there is an unmet clinical need for the development of novel pharmaceutical preparations of hydrocortisone, in order to guarantee a more physiological serum cortisol concentration time-profile.

9. Safety Considerations and Drug Interactions

Consequences of Chronic Hypercortisolism

Chronically excessive cortisol release describes the condition of Cushing's syndrome. Cushing's syndrome may come about as a result of cortisol hypersynthesis, which may be generated by an adrenocortical tumour, or as the consequence of excessive stimulation of the adrenal cortex by ACTH.

Among the well-documented clinical consequences of chronic glucocorticoid excess: hypertension is present in about 80% of patients with Cushing's syndrome and can lead to significant morbidity and mortality. Other documented effects include increased susceptibility to infections, osteoporosis, glucose dysregulation, muscle wasting, and mood disturbances.

Consequences of Hypocortisolism

Low-normal or subnormal plasma cortisol plus elevated ACTH is the hallmark of Addison's disease. Injection of high doses of ACTH does not lead to a rise in plasma cortisol in these patients. Insufficient cortisol (as in Addison's disease) can lead to unchecked inflammation and autoimmune activity.

Mineralocorticoid Receptor Activation at High Doses

When cortisol levels are high and 11β-HSD is saturated, cortisol can activate mineralocorticoid receptors. Usually, this is a result of treatment with exogenous glucocorticoids at supra-physiologic doses. This can lead to sodium retention, hypokalemia, and hypertension.

Pharmacokinetic Interactions: CYP Enzyme Induction

Induction of CYP3A4-mediated rapid inactivation of cortisol leads to a requirement for a 2- to 3-fold increased glucocorticoid replacement dose when treatment occurs with agents that induce CYP3A4 (e.g., mitotane). This interaction is clinically significant for patients on glucocorticoid replacement who are co-prescribed CYP3A4 inducers (such as rifampicin, certain anticonvulsants, and others).

HPA Axis Suppression from Exogenous Glucocorticoids

Prolonged glucocorticoid use or chronic stress can suppress the HPA axis, impairing cortisol production. Abrupt discontinuation of exogenous glucocorticoids after prolonged use can precipitate adrenal insufficiency due to suppression of endogenous cortisol synthesis — a well-established and clinically critical safety concern.

Assay Interference

Automated immunoassays lack specificity and show significant cross-reactivity due to interactions with structural analogs of cortisol, and show differences between assays. Liquid chromatography–tandem mass spectrometry (LC-MS/MS) can improve specificity and sensitivity. Clinicians interpreting cortisol levels should be aware that immunoassay-based results may be confounded by the presence of exogenous synthetic glucocorticoids or endogenous cortisol analogs.

Timing Considerations in Replacement

It has been shown that glucocorticoid replacement regimens that result in exposure to exogenous glucocorticoids late in the day, when physiological levels would normally be low, worsen carbohydrate handling compared with regimens where the dosage is delivered earlier.

References

Health Conditions

Health conditions that Cortisol may help support.

No conditions available.

Body Systems

Body systems that Cortisol may help support.

No body systems available.